Meropenem

證據等級: L5

預測適應症: 10 個

Meropenem: From Serious Bacterial Infections to Bacterial Arthritis

One-Sentence Summary

Meropenem is a broad-spectrum carbapenem antibiotic used globally to treat serious Gram-negative and anaerobic bacterial infections, including hospital-acquired pneumonia, complicated intra-abdominal infections, and sepsis. The TxGNN model predicts it may be effective for Bacterial Arthritis, with 1 clinical trial and 20 publications currently supporting this direction. The retrieved clinical trial evaluates a different drug (levofloxacin) in a different population; the strongest supporting evidence comes from observational studies on musculoskeletal melioidosis where meropenem is already standard of care.

Quick Overview

Item	Content
Original Indication	No Philippines registration; globally indicated for serious Gram-negative bacterial infections
Predicted New Indication	Bacterial Arthritis
TxGNN Prediction Score	99.92%
Evidence Level	L3
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Meropenem is a carbapenem β-lactam antibiotic that exerts bactericidal activity by covalently binding to penicillin-binding proteins (PBPs) — particularly the transpeptidases responsible for peptidoglycan cross-linking in the bacterial cell wall. Disruption of this cross-linking halts cell wall synthesis, leading to osmotic instability and bacterial lysis. This mechanism is active against a broad spectrum of Gram-negative pathogens (Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp.) and anaerobes, including many multidrug-resistant (MDR) strains that produce extended-spectrum β-lactamases (ESBLs).

Bacterial (septic) arthritis is most commonly caused by Staphylococcus aureus, but Gram-negative organisms account for a clinically meaningful subset of cases — particularly in neonates, elderly patients, immunocompromised hosts, intravenous drug users, and individuals with penetrating joint trauma. In these populations, MDR Gram-negative pathogens may render first-line antibiotics ineffective, creating a clear niche for carbapenem therapy. The synovial membrane’s rich vascularity supports adequate antibiotic penetration; pharmacokinetic data (PMID 38649034) confirm that IV meropenem achieves effective concentrations in inflamed tissues, supporting the mechanistic rationale.

The strongest direct clinical link emerges from melioidosis (Burkholderia pseudomallei infection), a tropical infectious disease with high prevalence in Southeast Asia and Northern Australia. Musculoskeletal involvement — including septic arthritis and osteomyelitis — is a recognized complication of melioidosis, and meropenem is the standard intensive-phase treatment. A retrospective series of 22 musculoskeletal melioidosis cases (PMID 39489417) directly demonstrated 100% meropenem susceptibility among all causative isolates, providing a concrete, clinically validated foundation for the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01371656	Phase 3	Completed	624	Evaluated levofloxacin (not meropenem) for bacteremia prevention in children with acute leukemia or undergoing HSCT; indication is bacteremia prophylaxis, not bacterial arthritis treatment — provides indirect infectious disease background only (Relevance Grade: C)

Note: No clinical trials directly evaluating meropenem for bacterial arthritis are currently registered. The single retrieved trial is included for completeness but does not constitute direct evidence.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39489417	2024	Retrospective Review	Indian J Med Microbiol	22 culture-confirmed musculoskeletal melioidosis cases; 9 cases of septic arthritis; all B. pseudomallei isolates 100% susceptible to meropenem — strongest direct evidence
35146367	2021	Retrospective Cohort	Le Infezioni in Medicina	Characterised osteoarticular melioidosis patients; meropenem is the recommended intensive-phase treatment for bone and joint melioidosis
37713001	2024	Cohort	Eur J Orthop Surg Traumatol	Antibiogram for empiric antibiotic use in adult non-spinal orthopaedic infections including septic arthritis in a developing-world setting; meropenem consistently active against Gram-negative isolates
39193962	2024	Observational	Clin Laboratory	Pathogen distribution and antimicrobial resistance in bone and joint infections in children under 4 years; informs carbapenem reserve strategy for MDR Gram-negative pathogens
38649034	2024	PK Study	Int J Antimicrob Agents	Meropenem tissue penetration in inflamed lung model; IV meropenem achieves effective concentrations in inflamed tissue — supports pharmacokinetic rationale for joint space penetration
39681779	2025	PK Study	Clin Pharmacokinetics	Population PK of meropenem across the adult lifespan; age-adjusted dosing regimens identified to maintain effective drug exposures in elderly patients
33857030	2021	In vitro Study	J Bone Joint Surg Am	Thermal stability and elution kinetics of meropenem from PMMA bone cement; meropenem retains activity post-polymerization and shows sustained local release — supports local delivery in prosthetic joint infections
31319190	2019	Animal Study	Int J Antimicrob Agents	Colistin cement spacer combined with systemic meropenem for carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection in a rabbit model; combination therapy significantly reduced bacterial burden
38139869	2023	Case Report	Pharmaceuticals	First reported case of native hip septic arthritis caused by Bacillus pumilus and Paenibacillus barengoltzii in an immunocompetent adult; highlights the need for broad-spectrum coverage including carbapenems when unusual organisms are involved
36804370	2023	Review	Int J Antimicrob Agents	Off-label and formal antibiotic recommendations for MDR bacterial infections; carbapenems including meropenem identified as key options for ESBL- and carbapenemase-producing Gram-negative invasive infections

Philippines Market Information

Meropenem currently has no registered products in the Philippines (FDA Philippines). No license, brand name, or approved indication data is available for this market.

For reference, in markets where meropenem is approved (e.g., US FDA, EMA), registered indications include complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and bacterial meningitis. Bacterial arthritis is not a formally listed indication in any major jurisdiction, though its use in serious Gram-negative joint infections is supported by international infectious disease guidelines.

Safety Considerations

Please refer to the package insert for safety information.

The safety data for this Evidence Pack is incomplete. Philippines-specific prescribing information, key warnings, and contraindications have not yet been retrieved (Data Gap DG001). A full safety evaluation cannot proceed until this data is obtained.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic and pharmacokinetic basis for meropenem in bacterial arthritis is scientifically sound, particularly for Gram-negative and MDR pathogen-driven septic arthritis; observational cohort data from musculoskeletal melioidosis directly confirm 100% pathogen susceptibility, providing a clinically meaningful L3-level evidence signal that justifies cautious advancement.

To proceed, the following is needed:

Safety data (Blocking): Retrieve the Philippines package insert or equivalent WHO/US prescribing information to document contraindications, key warnings, and drug interactions — this is currently blocking a formal safety evaluation
Mechanism of action documentation: Query DrugBank (DB00760) for complete MOA, pharmacodynamic targets, and toxicity profile
Direct clinical trial evidence: No Grade A/B trials currently exist for meropenem specifically in bacterial arthritis; a prospective study protocol targeting Gram-negative septic arthritis would be required to elevate evidence to L1/L2
Philippines epidemiology: Conduct local assessment of septic arthritis pathogen distribution and antimicrobial resistance patterns to confirm unmet clinical need in the Philippines context
Regulatory pathway: Since meropenem is not currently registered in the Philippines, a new drug application (NDA) or compassionate use / expanded access framework must be established before any formal clinical deployment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.